Artificial lung-like device developer ALung Technologies raised $2.6 million in a new round of debt and options financing, according to an SEC filing posted this week.
The Pittsburgh, Penn.-based company is developing the Hemolung device, an extracorporeal carbon dioxide removal system that works by removing carbon dioxide and delivering oxygen directly to a patient’s blood via a small catheter inserted into the jugular or femoral vein.
ALung Technologies has not yet stated how it plans to spend money raised in the round.
Money in the round came from 37 unnamed sources, with the company seeking another $1.4 million before closing the round. The 1st sale in the round was reported on Dec. 27, according to the SEC filing.
Last month, ALung Technologies said it raised $2.6 million in a new round of financing, according to an SEC filing posted this week.
Last January, ALung Technologies reported raising $10.8 million in a round of debt financing.
A month earlier, the company said its Hemolung RAS extracorporeal carbon dioxide removal device was selected for use in the world’s 1st pivotal trial of ECCO2R technology used to treat patients with acute respiratory failure.